Back to Search
Start Over
How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
- Source :
- Expert Opinion on Pharmacotherapy; Apr2024, Vol. 25 Issue 5, p571-584, 14p
- Publication Year :
- 2024
-
Abstract
- Tauopathies are a spectrum of clinicopathological neurodegenerative disorders with increased aggregates included in glia and/or neurons of hyperphosphorylated insoluble tau protein, a microtubule-associated protein. Progressive supranuclear palsy (PSP) is an atypical dopaminergic-resistant parkinsonian syndrome, considered as a primary tauopathy with possible alteration of tau isoform ratio, and tau accumulations characterized by 4 R tau species as the main neuropathological lesions. In the present review article, we analyzed and discussed viable disease-modifying and some symptomatic pharmacological therapeutics for PSP syndrome (PSPS). Pharmacological therapy for PSPS may interfere with the aggregation process or promote the clearance of abnormal tau aggregates. A variety of past and ongoing disease-modifying therapies targeting tau in PSPS included genetic, microtubule-stabilizing compounds, anti-phosphorylation, and acetylation agents, antiaggregant, protein removal, antioxidant neuronal and synaptic growth promotion therapies. New pharmacological gene-based approaches may open alternative prevention pathways for the deposition of abnormal tau in PSPS such as antisense oligonucleotide (ASO)-based drugs. Moreover, kinases and ubiquitin-proteasome systems could also be viable targets. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14656566
- Volume :
- 25
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Expert Opinion on Pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 177561514
- Full Text :
- https://doi.org/10.1080/14656566.2024.2345734